BH-30236
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Near Add Your Location
Sorting 18 by
Center of Excellence
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Accepting patients
Center of Excellence
Roswell Park Cancer Institute
Buffalo, NY
- Accepting patients
Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ
- Accepting patients
- Show Principal Investigator
Center of Excellence
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL
- Accepting patients
Center of Excellence
- Accepting patients
Memorial Sloan Kettering Bergen
Montvale, NJ
- Accepting patients
- Show Principal Investigator
Center of Excellence
- Accepting patients
Center of Excellence
Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.